TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02439255

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Phytochemical
Description: Given black raspberry (BRB) nectar per oral (PO)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Screening Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Screening Questionnaire Administration
Description: Ancillary studies
Study: NCT01671475

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: microEEG (Bio-Signal microEEG)
Description: At the core, the Bio-Signal microEEG, is an FDA approved miniature, battery-operated, multi-channel, and portable system that records wideband bioelectric signals. The microEEG combines the characteristics of low noise and small size, due to a number of fundamental design characteristics. It records, amplifies, and digitizes the signals at a point very close to the electrodes. This allows the length of the wires between electrodes and the recorder's amplifiers to be very short, keeping them out of the way. Short wires also reduce any inconvenience signal artifacts or other problems that may be associated with the length of the wires. The microEEG's dimensions are about 2x2x1.
Study: NCT05980221

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Metabolomics
Description: Plasma samples taken for the investigation of the metabolome

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Metabolomics
Description: Plasma samples taken for the investigation of the metabolome

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Metabolomics
Description: Plasma samples taken for the investigation of the metabolome

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: 13C MTGT
Description: sequential breath samples taken for investigation of PEI (reference test)

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: 13C MTGT
Description: sequential breath samples taken for investigation of PEI (reference test)

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: 13C MTGT
Description: sequential breath samples taken for investigation of PEI (reference test)
Study: NCT02158065

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Coaching program
Description: The coaching program consists of a (1) Step counter used as a coaching activity monitor to collect number of steps walked by the patients and (2) the Linkcare System, a mobile phone or tablet PC placed in the patient's home to collect data from the step counter. The system will set a daily activity goal for the patient based on achieved activity levels which will be measured by the step counter. Patients will also receive feedback, motivational and educational messages and direct calls from the coaching team at each institution.
Study: NCT04210856

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Contemplative landscape exposure
Description: landscapes classified as contemplative (through a CLM psychometric measure) are expected to elicit different brainwave oscillations as compared to non-contemplative ones.
Study: NCT00973271

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 435 mg DCCR
Description: 435 mg diazoxide choline

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 135 mg fenofibric acid
Description: 135 mg fenofibric acid
Study: NCT02999217

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Iron isomaltoside
Description: Intravenous injection 1 g given postoperatively in the recovery ward.~Blood tests including red blood cell count, plasma ferritin, haemoglobin, haematocrit, mean corpuscular volume, mean haemoglobin concentration are made 1 day preoperatively, day 1, day 3 postoperatively, day of discharge and 1 month after discharge.~Reticulocyte count and reticulocyte haemoglobin concentration tests are made on the day of discharge and 1 month after discharge.~Count of total consumption of intravenous blood products. Count of total intravenous fluids. Clinical recovery and complications. Duration of hospital stay.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Intravenous injection given postoperatively in the recovery ward.~Blood tests including red blood cell count, plasma ferritin, haemoglobin, haematocrit, mean corpuscular volume, mean haemoglobin concentration are made 1 day preoperatively, day 1, day 3 postoperatively, day of discharge and 1 month after discharge.~Reticulocyte count and reticulocyte haemoglobin concentration tests are made on the day of discharge and 1 month after discharge.~Count of total consumption of intravenous blood products. Count of total intravenous fluids. Clinical recovery and complications. Duration of hospital stay.
Study: NCT00694811

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Re-feeding duration
Description: 1 or 6 weeks of re-feeding after VLED-induced weight loss

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Re-feeding duration
Description: 1 or 6 weeks of re-feeding after VLED-induced weight loss
Study: NCT01452490

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Diode Laser Treatment
Description: Laser treatment once every 6 weeks, for a total of 4 treatment sessions
Study: NCT03486340

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cardiologic assessment
Description: Aggressive ischemic risk factor management
Study: NCT03949322

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adapted Physical Activity Program
Description: The sessions in this program are similar to the adapted physical activity sessions already offered by sports therapy practitioners. This is an aerobic exercise session, with Nordic walking, and a combined session of muscle building and breathing exercises.
Study: NCT00836810

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Timed Release Tablet Prednisone
Description: Dose: 7mg, taken at 10pm every night for 2 weeks in the form of oral tablets.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone
Description: Dose: 7mg, taken in the morning for 2 weeks in the form of oral tablets.
Study: NCT03229798

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sumatriptan Succinate Oral Tablet
Description: Sumatriptan succinate commercial Imitrex 100 mg tablet

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Transdermal delivery of sumatriptan succinate
Description: Sumatriptan succinate transdermal drug delivery system

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Transdermal delivery of sumatriptan succinate
Description: Sumatriptan succinate transdermal drug delivery system

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Transdermal delivery of sumatriptan succinate
Description: Sumatriptan succinate transdermal drug delivery system

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Transdermal delivery of sumatriptan succinate
Description: Sumatriptan succinate transdermal drug delivery system

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Transdermal delivery of sumatriptan succinate
Description: Sumatriptan succinate transdermal drug delivery system
Study: NCT05548530

Intervention type: PROCEDURE
Intervention: Stereotactic intracranial hematoma puncture
Description: Check the CT scan of the patient's brain, find out the largest hematoma level of the patient, measure the coordinates of the puncture center, locate and mark the skull surface according to the coordinates obtained from the measurement, select the puncture point under the stereotaxic instrument, and mainly avoid important blood vessels , nerves and functional areas. Use an electric drill to drill the puncture needle into the center of the hematoma, and slowly aspirate the hematoma from the side hole until the suction stops when there is resistance. The residual hematoma in CT and the location of the drainage tube were determined, and the position of the puncture needle was adjusted for the situation of brain CT. After the operation, according to the re-examination of cranial CT, urokinase was injected into the hematoma cavity through the drainage tube to dissolve the residual hematoma, and the operation process strictly followed aseptic operation.

Intervention type: PROCEDURE
Intervention: decompressive craniectomy
Description: Prior to the procedure, all patients obtained endotracheal intubation under general anesthesia following the informed consent provided by their family members. Upon identifying the hematoma's location through CT imaging, the surgeon made a linear or horseshoe-shaped incision on the scalp and subsequently opened the dura mater after creating a bone flap. The hematoma was punctured using a brain needle, allowing for effective decompression. The cerebral cortex was incised along the cerebral gyri, facilitating the separation of brain tissue to eliminate residual hematoma. Once hemostasis was ensured within the operative area, a silicone drainage tube was inserted, and the cranial bone flap was restored to its original position. In cases of severe brain edema or cerebral herniation, bone flap decompression was performed.

Intervention type: PROCEDURE
Intervention: Neuroendoscopic
Description: The patient's preoperative CT and MR imaging data were fused with a neuronavigation system to avoid important functional areas and select the closest point of the hematoma to the cortex as the location point. Routine craniotomy was performed with a 2\*3 cm bone window, the puncture direction was repositioned by neuronavigation, the sheath was placed at the center of the hematoma, the core was removed, the endoscope was gradually aspirated, and the bleeding was stopped with electrocoagulation if there was considerable active bleeding. A drainage tube was placed, the bone flap was reset after surgery, and the scalp was sutured.
Study: NCT01577043

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Racecadotril
Description: Racecadotril, 30 mg per sachet, dosage 1.5 mg./kg./day

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: cornstarch powder diluted in distilled water, dosage 2.5 ml per dose
Study: NCT00895024

Intervention type: BEHAVIORAL
Intervention: Phone Interview/Questionnaire
Description: 35-minute questionnaire over the phone.
Study: NCT03429309

Intervention type: DRUG
Group type: OTHER
Intervention: Propofol
Description: Anesthesia was induced by intravenous infusion of propofol via the syringe pump at a rate of 30 mg/kg/h.
Study: NCT01702038

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 1000 mg administered intravenously
Study: NCT00733460

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BFPET
Study: NCT00607035

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olmesartan medoxomil ＋Azelnidipine
Description: The ARB plus CCB combination therapy group is administered olmesartan 20 mg/day and azelnidipine 16 mg/day for 6 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olmesartan medoxomil + Hydrochlorothiazide
Description: The ARB plus Diuretics combination therapy group is administered olmesartan medoxomil 20mg/day and hydrochlorothiazide 12.5mg/day for 6 months.
Study: NCT01133613

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bone morphogenetic protein 7
Description: Single intraarticular injection of BMP-7 or placebo on Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bone morphogenetic protein 7
Description: Single intraarticular injection of BMP-7 or placebo on Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bone morphogenetic protein 7
Description: Single intraarticular injection of BMP-7 or placebo on Day 1
Study: NCT06250075

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Formulation with probiotics
Description: Lactobacillus acidophilus NCFM®, Lactobacillus paracasei Lpc-37 ™, Bifidobacterium lactis Bi-04™, Bifidobacterium lactis Bi-07™, Bifidobacterium bifidum Bb-02™)

Intervention type: DIETARY_SUPPLEMENT
Group type: SHAM_COMPARATOR
Intervention: Formulation with probiotics
Description: Lactobacillus acidophilus NCFM®, Lactobacillus paracasei Lpc-37 ™, Bifidobacterium lactis Bi-04™, Bifidobacterium lactis Bi-07™, Bifidobacterium bifidum Bb-02™)
Study: NCT00973271

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebos matching each of 2 doses of DCCR and 135 mg fenofibric acid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebos matching each of 2 doses of DCCR and 135 mg fenofibric acid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebos matching each of 2 doses of DCCR and 135 mg fenofibric acid
Study: NCT03048240

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: perPDT
Description: The protocol requires the realization of specific procedures in addition to the usual care.~The per-operative photodynamic therapy (perPDT) added to surgery for glioblastoma excision. The patient will receive 5-ALA (5- alanine ,GLIOLAN drinkable) 4h before surgery + lighting of the tumor bed by a light source (laser) at the end of resection (Prolonged surgery of 45 minutes).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLIOLAN
Description: patient will receive 5-ALA (5- alanine ,GLIOLAN drinkable) 4h before surgery
Study: NCT03527446

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sprint Interval Training
Description: The 4-week sprint interval intervention will consist of a work-rest ratio of four 30-s intervals of exercise at maximal capacity and 4-min of passive recovery at 50% of maximal capacity between intervals. There will be three sessions per week.
Study: NCT04229017

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Posterior Cervical Stabilization System (PCSS)
Description: Posterior Cervical Stabilization System (PCSS) is non-segmental instrumentation with integrated screw fixation intended to provide immobilization and stabilization of spinal segments. PCSS achieves bilateral facet fixation by spanning the interspace at each level with points of fixation at each end of the construct.
Study: NCT04275518

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APG-115
Description: APG-115 orally once daily from Days 1 to 7 every 28 days.
Study: NCT06250075

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Formulation with probiotics
Description: Lactobacillus acidophilus NCFM®, Lactobacillus paracasei Lpc-37 ™, Bifidobacterium lactis Bi-04™, Bifidobacterium lactis Bi-07™, Bifidobacterium bifidum Bb-02™)
Study: NCT00973271

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebos matching each of 2 doses of DCCR and 135 mg fenofibric acid

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: atorvastatin
Description: 20 mg atorvastatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: atorvastatin
Description: 20 mg atorvastatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: atorvastatin
Description: 20 mg atorvastatin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: atorvastatin
Description: 20 mg atorvastatin
Study: NCT04275518

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APG-115
Description: APG-115 orally once daily from Days 1 to 7 every 28 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: 75 mg/m\^2 SC QD on Days 1- 7 (28-day cycle)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: 1g/m\^2 IV QD on Days 3-7 (28-day cycle)
Study: NCT03597724

Intervention type: OTHER
Intervention: Questionnaire composed of 13 choice questions.
Description: In this Discrete Choice Experiment (DCE), patients will be asked to choose which one of two hypothetical patients (Patient A and Patient B) suffering from sarcopenia with different levels of outcomes deserves the most the treatment. After completion of the choice tasks, respondents will be asked how difficult they found the choice tasks on a seven-point scale and to questions on their socio-economic and disease characteristics.
Study: NCT01230671

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Yoga
Description: A 12 week yoga session will be offered to women with breast cancer.
Study: NCT02574780

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: complex physical therapy
Description: Compare the standard treatment of lymphedema, by complex physical therapy versus TFC associated with the upper limbs strengthening exercises.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: complex physical therapy
Description: Compare the standard treatment of lymphedema, by complex physical therapy versus TFC associated with the upper limbs strengthening exercises.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Evaluate treatment of lymphedema, with in the quality of life and depression
Description: evaluate through the questionnaires fatigue and quality of life of patients with lymphedema (FACT- F and Inventory BECK)
Study: NCT04540211

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab at a fixed dose of 1200 milligrams (mg) administered by intravenous (IV) infusion every 3 weeks (Q3W) on Day 1 of each 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiragolumab
Description: Tiragolumab at a fixed dose of 600 mg administered by IV infusion every Q3W on Day 1 of each 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel 175 mg/m\^2 administered by IV infusion on Day 1 of each 21-day cycle for 6 cycles.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Paclitaxel
Description: Paclitaxel 175 mg/m\^2 administered by IV infusion on Day 1 of each 21-day cycle for 6 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin 60-80 mg/m\^2 administered by IV infusion on Day 1 of each 21-day cycle for 6 cycles.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cisplatin
Description: Cisplatin 60-80 mg/m\^2 administered by IV infusion on Day 1 of each 21-day cycle for 6 cycles.
Study: NCT03286569

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Upper arch Wilson quadhelex appliance
Description: Upper arch Wilson quadhelex appliance

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Upper arch Wilson quadhelex appliance
Description: Upper arch Wilson quadhelex appliance
Study: NCT03206450

Intervention type: PROCEDURE
Intervention: Biospecimen Collection
Description: Undergo collection of blood and provide saliva and semen samples

Intervention type: OTHER
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT04678544

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Scalp cooling system 2
Description: The investigational device which will be used in this study is the Paxman Scalp Cooling System 2. This device is manufactured by: Paxman Coolers Limited. This is a free-standing, electrically-powered, mobile refrigeration unit which circulates a refrigerated liquid coolant, at a pre-set temperature and flow rate, through a cooling cap which is attached to, and covers, the top of the patient's head. The Paxman Scalp Cooling System is intended to be used for scalp cooling of patients who are receiving chemotherapy for the treatment of solid tumors, in order to reduce the risk of chemotherapy-induced alopecia.~After the RCT, 34 patients who were expected to receive 4, 6, or 8 cycles of chemotherapy with an anthracycline regimen were further enrolled in the intervention group as a single-arm trial.
Study: NCT04606849

Intervention type: OTHER
Group type: OTHER
Intervention: Physician Survey
Description: Our questionnaire includes questions on respondent demographics and Likert-style questions about respondent experiences with ePNa. We will validate our modified questionnaire by calculating component loadings and Cronbach Alphas (i.e., internal consistency) of Likert questions loading onto the same components.

Intervention type: DEVICE
Group type: OTHER
Intervention: ePNa-CheXED
Description: ePNa-CheXED will incorporate Stanford University's artificial intelligence CheXED model to provide electronic classification of chest images in \<1 second for elements of pneumonia diagnosis and treatment (radiographic pneumonia, single vs multiple lobes, and pleural effusion).
Study: NCT04665895

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate 100 mcg/blister oral inhalation powder/Respirent Pharmaceuticals
Description: twice daily inhalation throughout the study

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FLOVENT DISKUS® 100 mcg/blister oral inhalation powder/GSK
Description: twice daily inhalation throughout the study

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: twice daily inhalation throughout the study
Study: NCT02513251

Intervention type: OTHER
Intervention: Chronic pain
Description: Chronic pain patients would complete the Traditional Chinese-Cantonese version of Short Form McGill Pain Questionnaire
Study: NCT04025983

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: GastimunHp Plus
Description: Each sachet contains 6mg of IgY and 50 mg of heat-killed Lactobacillus johnsonii No. 1088.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo contains neither IgY nor L. johnsonii.
Study: NCT02574780

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Evaluate treatment of lymphedema, with in the quality of life and depression
Description: evaluate through the questionnaires fatigue and quality of life of patients with lymphedema (FACT- F and Inventory BECK)
Study: NCT03476668

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: MIRT
Description: 4-week multidisciplinary intensive rehabilitation treatment

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: MIRT
Description: 4-week multidisciplinary intensive rehabilitation treatment
Study: NCT00390598

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PEG (solution given 4 L)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: senna glycoside 36 mg and PEG (solution given 2 L)
Study: NCT02073110

Intervention type: DEVICE
Intervention: Percutaneous Optical Biopsy (OCT and DRS)